Biopharmaceutical company Biocon Biologics will sell its Indian branded formulations businesses to Eris Lifesciences in a deal worth Rs 1,242 crore ($150 million) The deal includes the acquisition of insulin brands Basalog and Insugen which Eris said will help its diabetes treatment franchise reach 10 billion rupees in revenue. The revenue in fiscal 2023 from the business that Biocon is selling accounted for 3.7 per cent of the Bengaluru-based company's consolidated